Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas E Witzig

Showing results (301-310 of 387) with videos related to

Pageof 39
Sort By:
Blood|February 6, 2014
GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical featuresTianjiao Wang, Andrew L Feldman, David A Wada, et al.
JCO Precision Oncology|November 22, 2024
Personalized Medicine in Histiocytic Disorders: Novel Targets in Patients Without MAPK AlterationsKatherine E R Smith, Aldo A Acosta-Medina, Surendra Dasari, et al.
Cancer Causes & Control : CCC|May 1, 2012
Early life sun exposure, vitamin D-related gene variants, and risk of non-Hodgkin lymphomaJennifer L Kelly, Matthew T Drake, Zachary S Fredericksen, et al.
American Journal of Hematology|February 18, 2017
Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphomaN Nora Bennani, Betsy R LaPlant, Stephen M Ansell, et al.
Blood Advances|October 18, 2021
Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomesAlessia Castellino, Yucai Wang, Melissa C Larson, et al.
Blood Advances|July 18, 2022
Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort studyAung M Tun, Arushi Khurana, Raphael Mwangi, et al.
Blood Cancer Journal|November 13, 2023
Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort studyAllison M Bock, Jennifer J Gile, Melissa C Larson, et al.
Mayo Clinic Proceedings|March 14, 2007
Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statementAngela Dispenzieri, S Vincent Rajkumar, Morie A Gertz, et al.
American Journal of Hematology|July 21, 2010
Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myelomaFrancesca Gay, S Vincent Rajkumar, Morton Coleman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2010
Vitamin D insufficiency and prognosis in non-Hodgkin's lymphomaMatthew T Drake, Matthew J Maurer, Brian K Link, et al.
Pageof 39

Showing results (301-310 of 387) with videos related to

Sort By:
Pageof 39
Blood|February 6, 2014
GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical featuresTianjiao Wang, Andrew L Feldman, David A Wada, et al.
JCO Precision Oncology|November 22, 2024
Personalized Medicine in Histiocytic Disorders: Novel Targets in Patients Without MAPK AlterationsKatherine E R Smith, Aldo A Acosta-Medina, Surendra Dasari, et al.
Cancer Causes & Control : CCC|May 1, 2012
Early life sun exposure, vitamin D-related gene variants, and risk of non-Hodgkin lymphomaJennifer L Kelly, Matthew T Drake, Zachary S Fredericksen, et al.
American Journal of Hematology|February 18, 2017
Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphomaN Nora Bennani, Betsy R LaPlant, Stephen M Ansell, et al.
Blood Advances|October 18, 2021
Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomesAlessia Castellino, Yucai Wang, Melissa C Larson, et al.
Blood Advances|July 18, 2022
Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort studyAung M Tun, Arushi Khurana, Raphael Mwangi, et al.
Blood Cancer Journal|November 13, 2023
Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort studyAllison M Bock, Jennifer J Gile, Melissa C Larson, et al.
Mayo Clinic Proceedings|March 14, 2007
Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statementAngela Dispenzieri, S Vincent Rajkumar, Morie A Gertz, et al.
American Journal of Hematology|July 21, 2010
Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myelomaFrancesca Gay, S Vincent Rajkumar, Morton Coleman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2010
Vitamin D insufficiency and prognosis in non-Hodgkin's lymphomaMatthew T Drake, Matthew J Maurer, Brian K Link, et al.
Pageof 39